Invivyd, Inc., a biopharmaceutical company, has announced a significant change in its executive leadership. David Hering, the CEO of Invivyd, has stepped down from his role and as a member of the company's Board of Directors, effective April 11, 2024. His employment with the company will officially end on May 11, 2024. The Board is actively searching for a permanent replacement. Concurrently, Jeremy Gowler, who has been with Invivyd as Chief Operating Officer and Chief Commercial Officer since December 2022, has been appointed as the Interim CEO. Gowler's extensive experience includes roles at Sandoz, a division of Novartis, and Emergent Biosolutions. He will continue to fulfill his previous roles while serving as Interim CEO and will collaborate with an executive committee for strategic...Show More

Invivyd, Inc., a biopharmaceutical company, has announced a significant change in its executive leadership. David Hering, the CEO of Invivyd, has stepped down from his role and as a member of the company's Board of Directors, effective April 11, 2024. His employment with the company will officially end on May 11, 2024. The Board is actively searching for a permanent replacement. Concurrently, Jeremy Gowler, who has been with Invivyd as Chief Operating Officer and Chief Commercial Officer since December 2022, has been appointed as the Interim CEO. Gowler's extensive experience includes roles at Sandoz, a division of Novartis, and Emergent Biosolutions. He will continue to fulfill his previous roles while serving as Interim CEO and will collaborate with an executive committee for strategic guidance. In addition, the Board has reduced its size from nine to eight members. The company has also issued a press release on April 12, 2024, detailing these management changes and highlighting the company's focus on delivering monoclonal antibody therapies for the prevention of COVID-19. Invivyd's lead product, PEMGARDA™, has shown promise in clinical trials and has been authorized for emergency use by the U.S. FDA for certain immunocompromised individuals.